difference between glp-1 and gip vs vs Dual Agonist Medications for Obesity | Holly Lofton MD, DABOM posted on the topic Casa de Sante Shop UNITS:100 Capsules glp-1 intestinal paralysis legal

difference between glp-1 and gip vs vs Dual Agonist Medications for Obesity | Holly Lofton MD, DABOM posted on the topic Casa de Sante Shop UNITS:100 Capsules glp-1 intestinal paralysis legal

glp-1 intestinal paralysis legal team in kentucky attorney glp-1 intestinal paralysis lawyer kentucky West Virginia GLP-1 Lawyer kentucky glp-1 ...

Phase 2 Trial Design Participants: 338 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself

Casa de Sante Shop

UNITS:100 Capsules

The human trials dosed daily for about three months before measuring anything